Abstract:Background: Lung Cancer is the most common cancer in China. Brain metastasis(BM) is the main reason for treatment failure of advanced lung cancer and treatment strategy is unclear in real world practice. Recently, some data showed that EGFR-TKI was an efficient option for NSCLC BM patients. Further evidence on EGFR-TKI plus standard therapy in clinical practice is highly expected. Methods: Based on our clinical database, we collected the clinical data of patients diagnosed with NSCLC and BM during 2014 and 2017. The therapeutic effectiveness was compared between the chemoradiation and chemoradiation + EGFR-TKI. Log-rank test was used in the comparison of the two groups. Cox's proportional hazard models were used in the factor analyses. Results: Total 153 patients were analyzed in the study, 61 patients treated by chemoradiation and 92 patients by chemoradiation + EGFR-TKI. Baseline characters of age, location and T stage of primary disease, and metastatic numbers were balanced in two groups. Gefitinib is the most frequently used TKI in clinical practice, composing about 48%(44/92). In chemoradiation + EGFR-TKI, 72 patients were performed with EGFR gene test and of them, 56 patients (78%) were EGFR positive. In chemoradiation, 29 patients were performed with EGFR gene test and 2 patients (6.9%) were EGFR positive. EGFR positive rate was 57% (58/101) in the total patients. The OS trend obviously showed that patients got more advantage from chemoradiation + EGFR-TKI compared with chemoradiation. Median OS was 27.0 months in the chemoradiation + EGFR-TKI and 16.6 months in the chemoradiation. Subgroup 24 months survival rate analysis of Gefitinib vs other TKI is 0.732 and 0.427, p = 0.0124. This preliminary analysis indicated that adding TKI to chemoradiation treatment could improve OS (hazard ratio [HR] 1.887) on NSCLC BM patients. Conclusions: The first analysis presents the survival benefit of EGFR-TKI plus standard treatment on NSCLC BM patients. Further data from this real-world study will be generated as we continue recruiting more patients in near future. Legal entity responsible for the study: Oncology Department, Tangdu Hospital affiliated with the PLA Airforce Medical University Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest.

Epidermal Growth Factor Receptor (egfr)–tyrosine Kinase Inhibitors (tkis) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Combination Therapy of Brain Radiotherapy and EGFR-TKIs is More Effective Than TKIs Alone for EGFR-mutant Lung Adenocarcinoma Patients with Asymptomatic Brain Metastasis

Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis

EGFR-TKIs Plus Bevacizumab Demonstrated Survival Benefit Than EGFR-TKIs Alone in EGFR-mutant NSCLC Patients with Multiple Brain Metastases

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Treatment of Brain Metastasis from Non-Small Cell Lung Cancer

EGFR-Tyrosine Kinase Inhibitor Combined with Radiotherapy in 105 Patients of Lung Adenocarcinoma with Brain Metastasis: A Retrospective Study of Prognostic Factor Analysis

EGFR TKIs Plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases

Bisphosphonates Enhance Antitumor Effect of Egfr-Tkis in Patients with Advanced Egfr Mutant Nsclc and Bone Metastases

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment A cohort study

Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non–Small-cell Lung Cancer on Progression-free and Overall Survival

P3.02b-076 Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases

Superior Efficacy of Immunotherapy‐based Combinations over Monotherapy for EGFR‐mutant Non‐small Cell Lung Cancer Acquired Resistance to EGFR‐TKIs

211P First Analysis of a Real-World Study to Explore the Character and Treatment Outcome of Epidermal Growth Factor Receptor (Egfr)-Tyrosine Kinase Inhibitor (TKI) on Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases (BM)

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR-mutated NSCLC Patients with Brain Metastases.

Concurrent Brain Radiotherapy and EGFR-TKI May Improve Intracranial Metastases Control in Non-Small Cell Lung Cancer and Have Survival Benefit in Patients with Low DS-GPA Score.

Efficacy of EGFR-TKI Therapy in Patients with Brain Metastases from Non-Small-cell Lung Cancer: A Meta-Analysis

Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation.

Early Radiation Therapy Combined with Egfr-Tki is Associated with Longer Survival in Egfr-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases

EGFR-TKI Therapy Prolongs Survival in Non-small Cell Lung Cancer Patients with Brain Metastases or Bone Metastases